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A B S T R A C T
Lung cancer is the leading cause of cancer death because of smoking and air pollution. Therefore, new ideas
should be provided for lung cancer treatment in which the delivery of anticancer drugs to the local tumor site
can be achieved. For this purpose, we propose the use of stereocomplexed spherical microspheres with sizes
between 0.5 and 10 μm loaded with doxorubicin (DOX) to be administered through the nasal route. In order to
gain control over the microsphere morphology, size, and drug loading capacity, we systematically studied the
influence of the solvent used for preparation and the functionalization of their building blocks, namely poly-L-
lactide (PLLA) and poly-D-lactide (PDLA) with blocked or unblocked L-proline moieties. We could demonstrate
that DOX release is generally determined by the size of the microspheres. The antiproliferative activity of DOX
released from the different microspheres was shown in vitro using the A549 lung cancer cell line as a model.
Moreover, when in direct contact to the cancer cells, smaller microspheres were uptaken and could serve as a
reservoir for local drug release. Our findings not only provide a novel strategy to prepare PLA microspheres with
controllable morphology and release of anti-cancer drugs but also offer additional possibilities for the appli-
cation of stereocomplexed particles in anticancer therapy, with suitable sizes for nasal administration.
1. Introduction
Polylactide (PLA) is exploited as a biocompatible polymer matrix for
drug support in various biomedical applications [1–3]. In comparison
to materials solely composed of homocrystallites of poly(L-lactide)
(PLLA) or poly(D-lactide) (PDLA), the formation of stereocomplexes (sc-
PLA) between the equimolar mixture of PLLA and PDLA enhance the
hydrolysis resistance, thermal, and mechanical properties of sc-PLA
materials [4–6]. These differences allow for designing of PLA-based
materials with controllable thermal stability, mechanical properties or
biodegradation [7–9]. Moreover, the mixing of PLLA and PDLA en-
antiomers in the proper organic solvents induces the formation of ste-
reocomplexed microspheres [10–12]. For their application as drug de-
livery systems (DDS), it is crucial to obtain control over their size,
morphology, and porosity [8,13–15]. Recently, it was reported that the
dynamic interactions between vanillin versus imine chain end modified
PLLA and PDLA during the stereocomplex formation allows for the
control of the nanostructure morphology through reversible amine-
imine transformation [5]. However, there have been no reports of the
introduction of amino acid end groups into PLA to control the size,
morphology and drug release from stereocomplexed microspheres.
Therefore, we have introduced L-proline functionality to PLA backbone
because we assumed such functionality could be implemented as a
targeting moiety and enhanced anti-tumor efficiency of microparticles
[16], as it was demonstrated for amino acid functionalized prodrugs
against melanoma [17], cervical [18], and breast cancer [19].
Moreover, it has been shown for poly(lactide-co-glycolide) (PLGA)
microspheres, that the drug loading efficiency could be adjusted by the
type and the composition of organic solvents used for their preparation
[20]. Stereocomplexed PLA-based microspheres are typically prepared
in a single solvent, such as acetonitrile [12], tetrahydrofuran (THF)
[21] or 1,4-dioxane (DIOX) [22]. It is possible to assume that by the
dissolution of PLLA/PDLA in the binary mixture of these two solvents in
different ratios, it should be possible to additionally tune the particles
crystallinity [23] and encapsulation efficiency [20].
In this work, we propose to functionalize PLLA and PLDA with
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blocked or unblocked L-proline moieties in order to modulate the in-
teractions occurring between the polymer chains, while they precipitate
from mixture of organic solvents. To introduce amino acid end groups,
hydroxyl-Boc-L-proline was used as an initiator of both L-LA and D-LA
polymerization, and subsequently, this end group was deprotected to
yield L-proline functionalized PLAs. Such polymeric building blocks
were subsequently used for the preparation of doxorubicin (DOX)
containing stereocomplexed microparticles. We hypothesize that by
modulation of PLA end group functionality, namely, Boc-protected L-
proline versus unblocked L-proline PLAs, we should be able to control
the self-assembly of the polymeric building blocks [24], modulate the
morphology, and the drug release from stereocomplexed microspheres.
As a proof of concept, we performed DOX release experiments at phy-
siological conditions (pH 7.4) to probe if the size and morphology of
obtained stereocomplexed microspheres influence the DOX release.
Moreover, we investigated the efficiency of DOX-loaded microparticles
against A549 cell lines to analyse if the different size of microspheres
play a role in their antiproliferative activity. To the best of our
knowledge, this represents the first report on the development of ste-




Tin (II) octoate (2-ethylhexanoate) Sn(Oct)2 (commercial product
from Sigma-Aldrich) was purified by two consecutive high-vacuum
distillations at 140 °C/3× 10−3 mbar. The purified Sn(Oct)2, stored on
the vacuum line, was finally directly distributed into thin-walled vials
or ampules equipped with break-seals and then sealed off and stored at
−12 °C. l,L-lactide and d,D-lactide (99%, Purac, Netherlands) were
consecutively crystallized from dry 2-propanol and purified just before
use by sublimation in vacuo (10−3 mbar, 85 °C). Tetrahydrofuran (THF,
POCH, Gliwice, Poland, 99%) was kept for several days over KOH
pellets, filtered off, and refluxed over Na metal. Eventually, it was
distilled, degassed, and stored over a liquid Na/K alloy, and it devel-
oped a blue color. Methanol (POCH, Gliwice, Poland, pure p.a. grade),
1,4-dioxane (Sigma Aldrich), DOX⋅HCl (Sigma Aldrich), N-Boc-trans-4-
hydroxy-L-proline methyl ester (Sigma Aldrich), phosphate buffer saline
(PBS) pH 7.4 (Sigma Aldrich), Trifluoroacetic acid (Sigma Aldrich)
were used as received. As a cell culture medium for A549 cells, DMEM
supplemented with 10% FBS (Merck Millipore) and 1% Penicillin/
Streptomycin (Thermo Fisher Scientific) was used.
2.2. Ring-opening of L- and D-lactide
The linear PLLA and PDLA enantiomeric polymers were synthesized
according to a well-established procedure [22]. l,L-lactide or d,D-lactide
(5.70 g, 40mmol) was polymerized in THF at 80 °C with Sn(Oct)2 (1 mL
of 0.25mol L−1 solution in dry THF) and N-Boc-trans-4-hydroxy-L-
proline methyl ester (0.6 g, 2.36mmol) as components of the catalytic/
initiating system. The resulting polymer was dissolved in CHCl3 and
precipitated into methanol, separated by filtration and washed several
times with methanol. Boc-LP-PLA−OH, 1H NMR (CDCl3): 5.35 (br s,
1H, L-proline end group), 5.14 (1H, q, polymer), 4.31 (1H, q, end group
polymer) and (1H, t, L-proline end group), (1H, 3.8-3.6 (2H, m, L-pro-
line end group), 3.47 (3H, s, −OCH3 in L-proline end group) 2.33 (2H,
m, L-proline end group), 2.2 (2H, m, L-proline end group), 1.47 (3H, d,
polymer) 1.39–1.45 (Boc-protecting group).
2.3. Unblocking of L-proline functionalized PLAs
Deprotection of the Boc-protecting group was done as previously
described [24]. Briefly, polymer ester (0.5 g, 0.1 mmol) was dissolved
in CH2Cl2, and trifluoroacetic acid (TFA) was added. With vigorous
stirring, the process was conducted for 24 h. Subsequently, the PLLA or
PDLA was precipitated into a large excess of methanol, resulting in a
white powder. LP-PLA−OH, 1H NMR (CDCl3): 5.35 (br s, 1H, L-proline
end group), 5.14 (1H, q, polymer), 4.31 (1H, q, end group polymer) and
(1H, t, L-proline end group), (1H, 3.8-3.6 (2H, m, L-proline end group),
2.55 (2H, m, L-proline end group), 2.4 (2H, m, L-proline end group),
1.47 (3H, d, polymer).
2.4. Preparation of blank and DOX-loaded microparticles
Stereocomplex formation was carried out as follows: 50 mg of Boc-L-
proline/L-proline PLLA and 50mg of Boc-L-proline/L-proline PDLA were
dissolved separately in 1mL of DIOX, THF or in their binary mixtures
with different proportions of both solvents, then the solutions were
mixed together and (after short stirring) left at room temperature
without stirring. The initially clear mixture became turbid after
∼1–2 h. After ∼24 h the supernatant was removed by decantation, the
solid was washed with three portions (1 mL each) of fresh DIOX (or
THF) and dried at room temperature under a slight vacuum. The same
procedure was used for the DOX-loaded stereocomplexed micro-
particles in which for each enantiomer 50 μL of DOX solution in DMSO
was added.
2.5. Encapsulation efficiency
For the determination of drug loading content, the DOX-loaded NPs
solution was lyophilized and then dissolved in DMSO. The amount of
the encapsulated DOX was estimated by fluorescence spectroscopy
(λ=590 nm) according to a calibration curve. Encapsulation efficiency
(EE%) was calculated according to the following formula:
EE% = (Wt/Wi) × 100%
Where Wt is the theoretical amount of drug loaded in microparticles
and Wi is actual amount of drug loaded in microparticles.
2.6. In vitro drug release
To determine the release profile from stereocomplexed micro-
spheres composed of PLLA and PDLA with blocked and un-blocked L-
proline end groups were loaded with DOX. Then, 1.5mg of these mi-
crospheres were suspended in 1.5 mL of PBS buffer solutions in 2-mL
centrifuge tubes and incubated at 37 °C. At determined intervals, the
tubes were centrifuged at 6000 rpm for 5min using a Galaxy Ministar
microcentrifuge, and the supernatant was collected and replaced by an
equal volume of fresh buffer solution. The amount of released drug in
the supernatant was quantified from fluorescence emission spectra
measured on a Fluorog-3 (Horiba Jobin-Yvon) fluorimeter. The emis-
sion of the DOX was observed in the range of 590 nm upon excitation
with UV light of 490 nm. The percentage of DOX release at each time
was calculated by normalizing the data to the total amount of drug in
particles.
2.7. Cell viability assay
A549 cells (#ACC-107, Leibnitz Institute DSMZ – German Collection
of Microorganisms and Cell Cultures) were seeded into 96 well plates in
DMEM (Thermo Fisher Scientific) with 10% FBS (biowest) 1% peni-
cillin/streptomycin (Thermo Fisher Scientific) and grown over night at
37 °C and 5% CO2. Dry microspheres were weighed and transferred to
2mL microcentrifuge tubes. Particles were suspended in medium to a
final concentration of 1mg/mL and incubated at 37 °C. After 2 h, 6 h
and 24 h, 4×100 μL of each tube were removed and added to the cells
to 100 μL/well. Cells were incubated for 48 h with the conditioned
medium (extracts from the particles). Then, the supernatant was re-
moved and replaced with 100 μL/well fresh medium containing 10 μL/
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well MTT (5mg/mL in PBS, Sigma). After 4 h of incubation at 37 °C, the
supernatant was removed and replaced with isopropanol containing
0.04M HCl. Absorbance was read in a Tecan M200Pro microplate
reader at 570 nm. Absorbance from wells without cells were subtracted.
Relative viability was calculated as absorbance values of treated cells
divided by absorbance values of untreated cells and expressed as %.
2.8. Confocal laser scanning microscopy
A549 cells were seeded into 8-well μ-slides (ibidi) and grown over
night at 37 °C and 5% CO2. On the next day, a small amount of the dry
particles was added as a powder using a spatula and incubated for 24 h
at 37 °C and 5% CO2. After the incubation time, cells were washed 5x
with PBS to remove all loose particles and fresh medium containing
Hoechst 33342 (Sigma) to stain the nuclei was added. Cells were im-
aged live using a Leica SP8 confocal laser scanning microscope and
images were acquired using LASX software (Leica). Emitted DOX
fluorescence was collected from 569 nm to 690 nm (red channel, ex-
citation wavelength 561 nm). As the third channel (blue), Hoechst
fluorescence was collected from 413 nm to 485 nm (excitation 405 nm).
2.9. Characterization
1H NMR spectra were recorded in chloroform-d1 and 1,1,2,2-tetra-
chloroethane-d2 on a Bruker DRX500 spectrometer operating at
500MHz. Traces of the nondeuterated chloroform was used as an in-
ternal standard. The number-average molecular weights Mn of the
polymers were determined by size exclusion chromatography (SEC)
using an Agilent Pump 1100 Series (preceded by an Agilent G1379A
Degasser), equipped with a set of two PLGel 5 μ MIXED-C columns. A
Wyatt Optilab Rex differential refractometer and a Dawn Eos (Wyatt
Technology Corporation) laser photometer were used as detectors.
Dichloromethane was used as eluent at a flow rate of 0.8mL min−1 at
room temperature. Differential scanning calorimetry (DSC) analysis
was performed under nitrogen at a heating and cooling rate of 10 °C/
min on a DSC 2920 modulated TA Instruments. Both the temperature
and heat flow were calibrated with indium. Fourier-transform infrared
spectroscopy (FTIR) spectra were measured with a Nicolet 6700 spec-
trometer equipped with a deuterated triglycine sulfate (DGTS) detector.
Attenuated total reflectance (ATR) was used for IR measurements. The
spectra were obtained by adding 64 scans at a 2 cm−1 resolution.
Scanning electron microscopy (SEM) images were obtained with a Nova
Nano SEM 230 instrument (FEI company) equipped with SE Detector at
HV = 15 kV and low vacuum (0.3 Torr) with high resolution in lens
detector Helix (resolution approximately 2 nm). The samples were
prepared by fixing onto carbon adhesive tape and covering with a
conductive gold layer, and studied in low vacuum. The electron mi-
crographs were recorded with a resolution of 1024× 768 pixels.
3. Results and discussion
3.1. Microsphere preparation from L-proline functionalized PLLA/PDLA
Fig. 1 illustrates the synthesis of L-proline functionalized PLLA and
PDLA, the unblocking of L-proline end groups and the process of the
formation of microspheres from obtained enantiomeric PLAs. The main
concept relies on controlling the release of DOX from sc-PLA micro-
spheres prepared by mixing PLLA/PDLA with different end group
functionalities in two solvents in variable ratios (THF/DIOX). Towards
this aim, low molecular-weight PLLA and PDLA functionalized with L-
proline were synthesized by coordination polymerization [25] using
hydroxyl-functionalized, Boc-protected L-proline as an initiator of the
polymerization process. The single chromatographic peak in the range
of 2000–5000 g/mol and the relatively low dispersity (Đ<1.3-1.4),
respectively, indicate the good control over the polymerization process.
Macromolecular structure of synthesized PLAs was verified by 1H NMR
and MALDI-TOF (Figs. S1 and S2). Unblocking of the amine and car-
boxylic acid from Boc and tBu protecting groups can be readily con-
ducted under acidic conditions. Thus, the obtained PLLAs and PDLAs
were deprotected in dry CH2Cl2 in the presence of trifluoroacetic acid
(TFA) to afford the PLAs with unblocked L-proline end groups. Suc-
cessful deprotection of both PLLA and PDLA enantiomers was con-
firmed by comparing appropriate signals of the 1H NMR spectra given
in Fig. 1B. The Boc protecting group signals disappeared following
deprotection, causing a simplification in the 1.2–1.4 ppm region, and
disappearance of methyl group signal at 3.47 ppm. Moreover, the
characteristic L-proline end groups signals of CH2 protons were now
shifted from 2.2 to 2.33 and 2.4 to 2.55 ppm, respectively.
Subsequently, stereocomplexed microspheres were formed by
spontaneous precipitation of equimolar mixtures of PLLA and PDLA
from the solution of THF and 1,4-dioxane and their binary mixtures.
The ratios of THF and DIOX were selected as 10:0, 9:1, 7:3, 6:4, 5:5, 4:6,
3:7, 1:9, and 0:10. Equimolar mixtures of blocked/un-blocked L-proline
functionalized PLAs in chosen single solvent or mixture of organic
solvents (with or without DOX) were kept in this solution at ambient
temperature until precipitation occurred. After spontaneous precipita-
tion, the solvent was removed and the obtained microparticles were
dried at vacuum and ATR-FTIR analysis was used to confirm the pre-
sence of stereocomplex assemblies. As expected, a new band appears in
the spectrum of sc-PLA at 909 cm−1 derived from skeletal vibrations of
the β-helix (characteristic for stereocomplex), whereas the band char-
acteristic for enantiomeric α-helix (921 cm−1) completely disappears
[26], as shown in Figure S3.
3.2. Thermal properties of l-proline functionalized PLLA/PDLA
microspheres
To provide further proof of stereocomplexation, DSC was used to
investigate the thermal properties of stereocomplexed PLAs functiona-
lized with both blocked and un-blocked L-proline end groups.
Exemplary DSC traces of the enantiomeric components and stereo-
complexed microspheres before/after encapsulation of DOX are sum-
marized in Table S1-S4. Interestingly, the melting temperature of
polymeric components after deprotection is slightly higher by ∼4 oC
than the PLAs with Boc-protected end groups. This observation can
possibly indicate that supramolecular interactions between the un-
blocked L-proline end groups of PLAs enhanced the melting temperature
and crystallinity of obtained polymers [27]. Upon blending of obtained
PLLA and PDLA, the crystallinity and melting temperature of resulting
materials increases by ∼50–60 oC relative to that of the individual
components [13]. The Tm values of obtained stereocomplexed PLAs are
in the range of ∼198–209 °C in the first and second heating run of DSC,
which is much higher than that of homocrystallites of enantiomeric
PLAs (∼135–145 °C). The Tm and ΔHm values of the stereocomplexes
obtained via spontaneous precipitation from un-blocked l-proline PLAs
are higher in comparison to those with blocked L-proline end groups, as
shown in Fig. 2B/D and Table S1/Table S3. It is clear that the three
different interactions are possible between L-proline end-capped mac-
romolecules, namely hydrogen bonding, acid-base, and oppositely
charge ionic interactions [28]. These supramolecular bondings play an
important role in controlling their self-assembly [29] and enhance their
crystallization ability [10]. Apart from the influence of the functionality
of obtained PLAs on the crystallinity, these values can be tuned by
varying ratio of THF and DIOX used for their precipitation. The highest
crystallinity is observed for the stereocomplexes prepared in DIOX and
lowest for those precipitating from THF. There is also a clear trend in
which the crystallinity decreases upon addition THF to DIOX, however
only until a certain level (as shown in Table S1 and S3). Moreover,
melting peaks at temperatures characteristic for stereocomplexes were
observed in the first and second heating runs of DSC, therefore it can be
concluded that the stereocomplex formation is fully reversible [30].
The question arose how the addition of DOX would affect the
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Fig. 1. (A) Synthesis of Boc-L-proline functionalized PLAs and unblocking of the proline end groups, (B) 1H NMR spectra of PLAs before and after unblocking and (C)
SEC chromatograms of these PLAs. (D) Scheme of formation of sc-PLA microspheres from enantiomeric PLAs by spontaneous precipitation from solution.
Fig. 2. DSC thermograms of (A) Boc-L-proline and (C) L-proline functionalized PLAs and their stereocomplexes composed of PLAs with (B) blocked and (D) unblocked
proline end groups (the values for all samples are presented in Table S1-S4).
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stereocomplexation process and morphology of PLA particles during the
spontaneous precipitation of microspheres. For the microparticles
composed of PLAs with Boc-L-proline end groups, solely stereocomplex
crystallites are present in the first and second heating run of DSC and a
slight decrease of their crystallinity is observed after DOX encapsula-
tion. Whereas stereocomplexes of PLLA and PDLA without Boc-pro-
tected end groups prepared from THF and its mixture with DIOX exhibit
the formation of stereocomplex crystallites in the first heating run with
only a small fraction of homocrystallities. However, in the second
heating run of DSC, only signals characteristic for stereocomplexes are
observed. This indicates that more perfect sc-PLA crystals are formed
from the melt. The stereocomplexes composed of unblocked PLAs also
exhibit lower crystallinity and melting temperatures after addition of
DOX.
3.3. Morphological characterization of blank and DOX-loaded L-proline
functionalized PLLA/PDLA microspheres
Stereocomplexed microspheres composed of blocked/un-blocked L-
proline functionalized PLAs were prepared through spontaneous pre-
cipitation in THF, DIOX or in their mixture with different ratios. In our
previous work, we have shown that the enantiomeric PLAs self-as-
sembled into stereocomplexed microspheres in THF, whereas a worm-
like stereocomplexed nanostructure was formed in DIOX [21]. There-
fore, we anticipate that the different solvation of PLLA/PDLA macro-
molecules in the pure solvents and their binary mixtures would ad-
ditionally alter the morphology of obtained microparticles. The
morphology of the microspheres was characterized in detail by scan-
ning electron microscopy (SEM). After mixing of Boc-L-proline end-
capped PLLA and PDLA, three distinct morphologies were observed
depending on the solvent used for their preparation. Using THF, porous
microspheres with cracks are formed, whereas in DIOX, enantiomeric
PLAs self-assemble in the form of pac-man particles, and in the mixture
of the two solvents (THF/DIOX: 1:9) uniform microparticles with ap-
parent cracks on the surface are created, as shown in the Fig. 3. Further
increase in the THF content does not significantly change the mor-
phology of the uniform microspheres, except for the ratio 3:7, in which
ruptures on the surfaces of microspheres were observed (Figure S4).
The size of microspheres ranges from 5 to 10 μm, depending on the
method of preparation. Since there was only a slight difference in
morphology of microspheres after increasing the amount of THF in a
binary mixture of THF and DIOX, three formulations were used for the
preparation of DOX-loaded microspheres with different ratio of THF
and DIOX (10:0, 1:9, 0:10). The particles transform into regular parti-
cles after DOX encapsulation, in which small nanometer-sized pores are
present as shown in Figure S5. This could be attributed to the presence
of DOX which could influence the PLLA and PDLA self-assembly and
especially the hydrogen-bonds formation between enantiomeric PLAs
[31]. In addition, DOX encapsulation may have also an influence on the
surface structure of resulting microparticles [32,33]. Evaporation-
driven connective assembly in colloids is controlled by the inter-particle
potentials, which is influenced by the surface charge of particles and
surrounding media [34]. Therefore, a probable explanation for the
different morphology of the particles is the contribution of the DOX in
forming competitive hydrogen bonds with PLA macromolecules.
When the L-proline end groups in the PLA microspheres were un-
blocked, their morphology and size was significantly different from
microspheres containing PLAs with blocked end-groups (Fig. 4). Espe-
cially, the size of microparticles was lower after deprotection of PLA
end-groups and it was in the range 0.5 to 3 μm. We assume that the
hydrogen bonding interactions between PLA end groups allow for the
pre-organization of macromolecules in the first stage of their self-as-
sembly [22]. Such interactions were impossible in the case of PLAs with
Boc-L-proline end groups. Subsequently, during stereocomplexation
smaller particles are formed due to combination of cooperative inter-
actions of the enantiomeric PLA segments, as it was shown in previous
studies [10,35]. Ajiro et. al. observed that reversible transition imine-
vaniline transformation of PLA end-groups allows for the control over
the morphology of obtained materials [5]. This was attributed to the
difference of hydrophobic-hydrophilic balance after end group depro-
tection. We assume that our amino acid functionalized PLAs can behave
similarly and that the L-proline end groups are able to form hydrogen
bonds, allowing for the nanostructure organization of sc-PLA nano-
particles with sizes of about 30 nm which are the building blocks of
resulting microspheres [36]. Their size is significantly lower than those
with Boc-protected groups due to the extensive interactions of the end-
groups [21]. The size of particles prepared without DOX is quite similar
to blank microparticles and their size is in the range of 0.5 to 1.5 μm.
However, the size of microspheres prepared solely in DIOX after DOX
encapsulation is increased to about 3 μm whereas for those prepared in
the other solvent combination does not noticeably differ. Moreover,
porous pac-man like particles are formed exclusively in DIOX. There-
fore, it can be concluded that this kind of morphology is preferred in
DIOX, probably due to the solvation of polymers in this solvent which
influences the hydrogen-bond interactions between macromolecules
and their self-assembly [21]. After DOX encapsulation, the difference in
morphology is not as pronounced for THF and its binary mixture as for
the Boc-protected PLAs which is in agreement with the work of Pack et.
al. for PLGA/PLA microspheres in which the morphology depends on
the DOX distribution in the microspheres [33].
Fig. 3. (A–C) Morphology of the stereo-
complexed microspheres composed of Boc-
protected L-proline functionalized PLAs pre-
pared in THF, DIOX and their 9:1 binary mix-
ture and (D–F) their DOX-loaded counterparts.
The yellow numbers denote the respective
DOX encapsulation efficiency (%). The scale
bar denotes 5 μm. (For interpretation of the
references to colour in this figure legend, the
reader is referred to the web version of this
article).
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3.4. Encapsulation and in vitro drug release of L-proline functionalized
PLLA/PDLA microspheres
The effect of the different formulations of L-proline functionalized
PLLA/PDLA microspheres was investigated in terms of encapsulation
efficiency of DOX. All results are summarized in Table S5 and S6 and
given in Fig. 5. The encapsulation efficiency (EE) of DOX in micro-
spheres composed of Boc-protected l-proline PLAs was in the range of
50–68% and is highest for the microparticles prepared in THF. In
contrary, the situation is totally different for unblocked L-proline PLAs
in comparison to blocked ones for which DIOX gives the lowest value of
encapsulation efficiency (26%) whereas for THF the EE reaches a value
of 60%. In the binary mixture of these two solvents in which the ratio of
the THF/DIOX was 9:1, the value is slightly higher (∼75%) so even the
addition of such small amounts of THF can significantly enhance this
value for microspheres from L-proline PLAs. Subsequently, the release
of DOX from prepared microspheres was investigated in PBS at 37 °C.
The release of drug from microspheres composed of Boc-protected
PLLA/PDLA is relatively slow and ranging from 5 to 10% after 100 h, as
shown in Fig. 5A. The difference between various formulations is re-
latively low, however, the release was faster for particles prepared with
DIOX and its binary mixture. This can be attributed to the low specific
surface of particles and slow hydrolysis rate of microparticles [33].
However, the release from microspheres built from PLLA and PDLA
with un-blocked l-proline end groups is completely different and a
much faster and higher release of DOX ranging from 41 to 81% is ob-
served, as shown in the Fig. 5B. In the first 6 h, there is an initial burst
release and subsequently, DOX is released slowly over a period of ∼
100 h. However, the fastest release is observed for particles prepared in
THF, followed by those from the binary mixture of THF/DIOX and in
DIOX alone. We ascribe this phenomenon to the presumable difference
in drug accumulation in the microspheres composed of Boc-L-proline
PLAs versus L-proline PLAs and thus the drug may be released faster
from the microspheres composed of L-proline PLAs because it is located
Fig. 4. (A–C) Morphology of the stereo-
complexed microspheres composed of un-
blocked L-proline functionalized PLAs prepared
in THF, DIOX and their 9:1 binary mixture and
(D–F) their DOX-loaded counterparts. The
yellow numbers denote the respective DOX
encapsulation efficiency (%). The scale bar
denotes 5 μm. (For interpretation of the refer-
ences to colour in this figure legend, the reader
is referred to the web version of this article).
Fig. 5. In vitro release profiles of DOX from
stereocomplexed microspheres composed of
PLLA and PDLA functionalized with (A) Boc-L-
proline and (B) L-proline. Antiproliferative ac-
tivity of medium extracts of DOX-loaded ste-
reocomplexed microspheres composed of (C)
Boc-L-proline PLLA/PDLA and (D) L-proline
PLLA/PDLA after different incubation times in
medium to A459 cells after 48 h, as determined
by MTT test.
M. Brzeziński, et al. Colloids and Surfaces B: Biointerfaces 184 (2019) 110544
6
near the surface and initial burst release is observed [33,37]. As it was
described by Ito et. al. the release of the drugs depends on the dis-
tribution of the drug on the surface or in the interior of the particle
[20]. Therefore, the preparation method and PLAs used (with blocked
versus un-blocked end groups) allow to optimize the release from ob-
tained sc-PLAs microparticles due to the size of microparticles, the drug
distribution in their interior, and in the lower extent from morphology.
3.5. Anti-cancer effects of drug loaded PLLA/PDLA microspheres
In order to assess the cytotoxicity of stereocomplexed DOX-con-
taining microspheres in vitro, the viability of A459 cells incubated with
medium extracts of the obtained microspheres was evaluated using
MTT assay. After incubation of 1mg/mL of microparticles for 2 h at
37 °C, there was a slight reduction in cell viability, which was however
not increased after prolonged exposure times of 6 h to 24 h, as shown in
Figure S6. To test the cell proliferation inhibition activity of DOX de-
livered by the loaded stereocomplexed microparticles, A459 cells were
treated with medium extracts of Boc-protected L-proline and L-proline
functionalized PLLA/PDLA microspheres for 2, 6 and 24 h. The time-
dependent increase in cytotoxicity mediated by conditioned media
confirmed that functional DOX is successfully released to the medium
over time causing its concentration-dependent specific reduction in cell
viability. However, there is a marked difference between the set of
particles prepared from Boc-protected L-proline and L-proline functio-
nalized PLLAs/PDLAs, mainly due to the different size of microparticles
and the rate of DOX release. Moreover, the cell viability also differs
with the solvent used for the preparation of microparticles which de-
termines their structure and size. For the microspheres composed of
Boc-protected PLLA/PDLA, the highest antiproliferative activity was
observed for the particles prepared in DIOX, however, due to the slow
release of the DOX, complete cell death is not achieved over the course
of the experiment, as shown in Fig. 5C. This could be overcome by
applying the microparticles composed of unblocked L-proline functio-
nalized PLLAs/PDLAs for which high anti-cancer activity is observed, as
shown in Fig. 5D. This is correlated with the release profiles in which
the high amount of DOX is released during the 24 h of incubation in
PBS. However, the highest efficiency in killing cancer cells was ob-
served for the particles prepared in THF, followed by those from the
binary mixture of THF and DIOX and finally from 1,4-dioxane. This
shows the high influence of the size and morphology of obtained DOX-
loaded stereocomplexed microspheres for drug delivery to lung cancer
cells. Thus, it could be hypothesized that the optimal preparation
conditions and polymer functionalities determined the amount of de-
livering DOX to lung cancer cells and the efficiency of the potential
therapy.
To investigate the effect of the microsphere morphology on cells in
direct contact, we incubated the different DOX-loaded formulations for
24 h on A549 cells and observed them by confocal microscopy (Fig. 6
and Figures S8-S12). We can clearly see the DOX fluorescence asso-
ciated with the particles and the sizes and shapes similar to the ones
observed by SEM. The microspheres prepared from Boc-L-proline PLAs
were partly associated with the cells, leaving them however largely
unaffected (Fig. 6 A–C) consistent with the results from our cell viabi-
lity study. The smaller microspheres resulting from unblocked L-proline
PLAs however were uptaken by the cells and hence found within their
cytoplasm. It is well known that cellular uptake of microparticles is size
dependent [38], which is reflected here. Although free DOX is usually
found in the cell nucleus after diffusing into cells, we did not observe
clear DOX fluorescence in the nuclei for all formulations. However, the
cytotoxic effect of DOX is clearly seen on the cells treated with the
unblocked L-proline PLA microspheres (Fig. 6D–F) by their disturbed
cellular morphology such as membrane blebs and vacuolization as well
as detachment and lower cell density in the monolayer. We propose that
the particles can act as reservoirs for slow and steady drug release
closely associated or within the cells, but in this experiment, the in-
tracellular concentration of released DOX is not high enough to be
detected with the microscope. Consistent with the previously presented
results, the therapeutic effect of DOX on lung cancer cells appears to be
largest when delivered by the unblocked L-proline PLA microspheres
prepared in THF.
4. Conclusion
In summary, we have developed novel DOX-loaded stereo-
complexed microparticles with controlled size and microstructure for
use as drug delivery system in cancer therapy. This was done by ap-
plying different organic solvents, namely, THF, DIOX, and their binary
mixtures and by tuning the PLA end group functionality, namely, Boc-
protected L-proline versus unblocked L-proline PLAs. We systematically
Fig. 6. Confocal laser scanning microscopy
images of live A549 cells after 24 h of incuba-
tion with the differently formulated DOX
loaded microspheres. Boc-L-proline PLA mi-
crospheres prepared in (A) THF, (B) DIOX, (C)
DIOX/THF and (D–F) their unblocked L-proline
PLA counterparts. Merged color images of
transmitted light (grey), DOX fluorescence
(red) and Hoechst 33342 stained cell nuclei
(blue). Scale bar =10 μm. (For interpretation
of the references to colour in this figure legend,
the reader is referred to the web version of this
article).
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screened different conditions and found that the smaller particles are
obtained from unblocked L-proline PLAs, whereas their morphology is
determined by the solvent from which these particles are prepared.
Moreover, by tuning the preparation conditions we could modify the
DOX loading and release efficiency. Interestingly, in vitro experiments
in which we observed the highest efficiency for particles composed of L-
proline PLAs which can deliver DOX in the fastest manner, correlates
with their antiproliferative activity. Moreover, the size also determines
their uptake by lung cancer cells. These advantageous features indicate
that stereocomplexed microspheres can enhance the efficiency of che-
motherapy against lung cancer as these DOX-loaded microcarriers
could be potentially administrated to the lungs by inhalation.
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